Clinical development of P glycoprotein modulators in oncology

Novartis Foundation Symposium

Volumn 243, Issue , 2002, Pages 103-118

  Oza, Amit M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN DERIVATIVE; ENZYME INHIBITOR; GLYCOPROTEIN P; PACLITAXEL; TUMOR PROTEIN; VALSPODAR;

ANTIBODY SPECIFICITY; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DESIGN; DRUG RESISTANCE; FEMALE; HUMAN; MALE; METABOLISM; MULTIDRUG RESISTANCE; NEOPLASM; OVARY TUMOR; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS; CYCLOSPORINS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASMS; ORGAN SPECIFICITY; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL;

EID: 0036367871     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (46)

1. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH 1999 The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59:4237-4241
2. Arceci RJ 1993 Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81:2215-2222
3. Bartlett NL, Lum BL, Fisher GA et al 1994 Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12:835-842
4. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F 1991a In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51:4226-4233
5. Boesch D, Muller K, Pourtier-Manzanedo A, Loor F 1991b Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res 196:26-32
6. Boote DJ, Dennis IF, Twentyman PR et al 1996 Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14:610-618
7. Campos L, Guyotat D, Archimbaud E et al 1992 Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473-476
8. Collins HL, Fisher GA, Hausdorff J 1995 Phase I trial of paclitaxel in combination with SDZ PSC 833, a multidrug resistance modulator. Proc Am Soc Clin Oncol 14:A406
9. Covelli A 1996 SDZ PSC 833 investigator's brochure. Sandoz Pharma, Basel
10. Dalton WS 1993 Drug resistance modulation in the laboratory and the clinic. Semin Oncol 20:64-69
11. Del Poeta G, Stasi R, Aronica G et al 1996 Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukaemia. Blood 87:1997-2004
12. Dorr RT, Liddil JD, Trent JM, Dalton WS 1987 Mitomycin C resistant L1210 leukemia cells: association with pleiotropic drug resistance. Biochem Pharmacol 36:3155-3120
13. Epstein J, Xiao HQ, Oba BK 1989 P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 74:913-917
14. Erlichman C, Moore M, Thiessen JJ et al 1993 Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 53:4837-4842
15. Erlichman C, Moore M, Thiessen J et al 1994 A phase I trial of doxorubicin (DOX) and PSC 833, a modulator of multidrug resistance (MDR). Anticncer Drugs 5:A97
16. Fisher GA, Halsey J, Hausdorff J et al 1994 A phase I study of paclitaxel (Taxol®) in combination with SDZ PSC 833, a potent modulator of multidrug resistance (MDR). Anticancer Drugs 5:A99
17. Fojo AT, Ueda K, Salmon DJ, Poplack DG, Gottesman MM, Pastan I 1987 Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265-269
18. Ford IM, Hait WN 1990 Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 2:156-199
19. Fracasso PM, Fisher GA, Wiehl JG et al 1995 Phase I trial of paclitaxel and SDZ PSC 833 in patients with solid tumors. Proc Am Soc Clin Oncol 14:A1585
20. Fracasso PM, Brady MF, Moore DH et al 2001 Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 19:2975-2982
21. Giaccone G, Linn SC, Catimel G et al 1994 SDZ PSC 833 in combination with doxorubicin: A phase I and pharmacologic study in solid tumors. Anticancer Drugs 5:A98
22. Goldstein LJ, Galski H, Fojo A et al 1989 Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116-124
23. Hausdorff J, Fisher GA, Halsey J et al 1995 A phase I trial of etoposide with the oral cyclosporin SDZ PSC 833, a modulator of multidrug resistance (MDR). Proc Am Soc Clin Oncol 14:A407
24. Herweijer H, Sonneveld P, Baas F, Nooter K 1990 Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation of cyclosporine. J Natl Cancer Inst 82:1133-1140
25. Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, van der Valk P, Scheper RJ 1996 Major vault protein LRP-related multidrug resistance. Eur J Cancer 32A:979-984
26. Keller RP, Altermatt HJ, Nooter K et al 1992 SDZ-PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 50:593-597
27. Kornblau SM, Estey E, Madden T et al 1997 Phase I study of mitoxantrone plus etoposide with multidrug blockade by SZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15:1796-1802
28. Loe DW, Deeley RG, Cole SPW 1996 Biology of multidrug-resistance in tumor cells. Eur J Cancer 32A:945-957
29. Lum BL, Gosland MP 1995 MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 9:319-336
30. Lum BL, Kaubisch S, Yahanda AM et al 1992 Alteration of etoposide pharmacokinetics and pharmaocodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635-1642
31. Lum BL, Fisher GA, Hausdorff J et al 1994 The effect of oral SDZ PSC 833 on the pharmacokinetics (PK) of etoposide (E) during a phase I trial to modulate multidrug resistance. Anticancer Drugs 5:A102
32. Nitiss LJ, Beck WT 1996 Anti-topoisomerase drug action and resistance. Eur J Cancer 32A:958-966
33. Nooter K, Stoter G 1996 Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract 192:768-780
34. Pastan I, Gottesman M 1987 Multiple-drug resistance in human cancer. N Engl J Med 316:1388-1393
35. Patnaik A, Warner E, Michael M et al 2000 Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. J Clin Oncol 18:3677-3689
36. Pearce T, Israel R 1993 PSC 833 investigator's brochure. Sandoz Pharmceutical, East Hannover, NJ
37. Riordan JR, Ling V 1985 Genetic and biochemical characterization of multidrug resistance. Pharmacol Ther 28:51-75
38. Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, Blick M 1990 Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 21:787-791
39. Simon N, Dailly E, Combes O et al 1998 Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin. Br J Clin Pharmacol 45:173-175
40. Smith AJ, Mayer U, Schinkel AH, Borst P 1998 Availability of PSC 833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J Natl Cancer Inst 90:1161-1166
41. Sonneveld P, Marie J-P, Huisman C et al 1996 Reversal of multidrug resistance of SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 10:1741-1750
42. te Boekhorst PAW, van Kapel J, Schoester M, Sonneveld P 1992 Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype. Cancer Chemother Pharmacol 30:238-242
43. Thiessen JJ, Erlichman C, Moore MJ et al 1994 The pharmacokinetics and bioavailability of a new chemosensitizer, SDZ PSC 833, in patients with advanced bladder cancer. Anticancer Drugs 5:A101
44. Twentyman PR, Bleehen NM 1991 Resistance modification by PSC 833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 27:1639-1642
45. van Asperen J, van Tellingen O, Sparreboom A et al 1997 Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76: 1181-1183
46. Willman CL 1997 The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukaemia: studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol 34:25-33